Robert Torray’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$33.8M Sell
602,028
-43,397
-7% -$2.26M 4.55% 2
2026
Q1
$31M Sell
645,425
-98,930
-13% -$4.33M 4.54% 1
2025
Q4
$28.8M Buy
744,355
+41,472
+6% +$1.58M 4.12% 2
2025
Q3
$24.8M Buy
702,883
+14,107
+2% +$511K 3.36% 3
2025
Q2
$24.8M Sell
688,776
-173,242
-20% -$5.74M 3.6% 3
2025
Q1
$26.8M Buy
862,018
+178,011
+26% +$5.64M 4% 1
2024
Q4
$17.4M Sell
684,007
-173,912
-20% -$4.61M 2.5% 9
2024
Q3
$24.3M Buy
857,919
+164,361
+24% +$4.55M 3.4% 4
2024
Q2
$18.3M Buy
693,558
+23,498
+4% +$651K 2.73% 5
2024
Q1
$20.3M Buy
670,060
+164,320
+32% +$4.84M 3.05% 4
2023
Q4
$14.2M Buy
505,740
+93,107
+23% +$2.56M 2.3% 13
2023
Q3
$11.2M Sell
412,633
-1,182
-0.3% -$35.1K 1.98% 20
2023
Q2
$12.7M Buy
413,815
+276,643
+202% +$9.37M 2.2% 16
2023
Q1
$4.94M Sell
137,172
-199
-0.1% -$7.38K 0.89% 44
2022
Q4
$5.43M Sell
137,371
-1,653
-1% -$69K 0.98% 37
2022
Q3
$5.59M Buy
139,024
+12
+0% +$513 1.11% 33
2022
Q2
$5.84M Buy
139,012
+6,942
+5% +$285K 1.11% 34
2022
Q1
$5.14M Sell
132,070
-5,871
-4% -$231K 0.83% 45
2021
Q4
$5.5M Buy
+137,941
New +$5.36M 0.81% 51

Other funds holding RPRX

Robert Torray's RPRX Position: Q2 2026 in Review

Robert Torray reduced its Royalty Pharma (RPRX) stake by 6.7% in Q2 2026, selling an estimated $2.26M and leaving 602,028 shares worth $33.8M. The position accounts for 4.55% of the portfolio, ranked #2.

Robert Torray first reported a position in RPRX in Q4 2021 and has held it in 19 quarters since. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Robert Torray held 602,028 shares of Royalty Pharma worth $33.8M as of Q2 2026.
  • Robert Torray sold 43,397 Royalty Pharma shares in Q2 2026, an estimated $2.26M.
  • Royalty Pharma made up 4.55% of Robert Torray's portfolio in Q2 2026, its #2 holding.
  • Robert Torray first reported a position in Royalty Pharma in Q4 2021 and has held it in 19 quarters since.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Torray Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.